Latest stories on OTLK
Outlook Therapeutics announces Greg DiPasquale as chief commercial officer
The Fly56 · neutralproduct/pr
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
GlobeNewswire54 · neutralproduct/pr
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Business Insider54 · neutralproduct/pr
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire63 · neutralproduct/pr
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
TipRanks34 · bearishgeneral
Outlook Therapeutics, Inc. (OTLK) files 8-K
SEC 8-K34 · bearishgeneral
Outlook Therapeutics, Inc. (OTLK) files 8-K
SEC 8-K50 · neutralgeneral
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
GlobeNewswire55 · neutralgeneral
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
GlobeNewswire73 · bullishproduct/pr
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Business Insider73 · bullishproduct/pr
Outlook Therapeutics Announces CFO Transition and Board Change
TipRanks50 · neutralgeneral
Outlook Therapeutics, Inc. (OTLK) files 8-K
SEC 8-K50 · neutralgeneral
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
GlobeNewswire63 · neutralgeneral
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Business Insider56 · neutralgeneral
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire55 · neutralgeneral
Outlook Therapeutics Earnings Call: LYTENAVA Faces Test
TipRanks46 · neutralearnings
Brookline Capital cuts Outlook Therapeutics stock price target on model update
Investing.com Analyst Ratings34 · bearishanalyst
Outlook Therapeutics $100M Spot Secondary re-offered at 99c
The Fly28 · bearishgeneral
Outlook Therapeutics reports Q3 EPS (15c), consensus (8c)
The Fly34 · bearishearnings
Outlook Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue
Seeking Alpha67 · bullishproduct/pr
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings